Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001380349 | SCV001578353 | pathogenic | Combined immunodeficiency with skin granulomas; Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive | 2020-07-28 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the RAG2 protein. Other variant(s) that disrupt this region (p.Glu480*) have been determined to be pathogenic (PMID: 21624848, 29772310, 29772310). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has not been reported in the literature in individuals with RAG2-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change results in a premature translational stop signal in the RAG2 gene (p.Leu242Profs*3). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 286 amino acids of the RAG2 protein. |
| Baylor Genetics | RCV003473924 | SCV004200538 | likely pathogenic | Combined immunodeficiency with skin granulomas | 2023-10-09 | criteria provided, single submitter | clinical testing |